# EDGAR Filing Document

**Accession Number:** 0001711933
**File Stem:** 0001558370-23-002902
**Filing Date:** 2023-3
**Character Count:** 18998
**Document Hash:** 02ff5bc633c8c1bc9e34d0a36c9b2aae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-002902.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0001558370-23-002902

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230306

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230306

**DATE AS OF CHANGE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akoya Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001711933
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 475586242
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40344
- **FILM NUMBER:** 23708908

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762
- **BUSINESS PHONE:** 855.896.8401

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 6, 2023

**Akoya Biosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;**001-40344** | &nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;**47-5586242** |
| &nbsp;&nbsp;(State or other jurisdiction<br>of incorporation) |  | &nbsp;&nbsp;(Commission<br>File Number) |  | &nbsp;&nbsp;(IRS Employer<br>Identification No.) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**100 Campus Drive, 6th FloorMarlborough, MA** | &nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp;** | &nbsp;&nbsp;**01752** |
| &nbsp;&nbsp;(Address of principal executive offices) |  | &nbsp;&nbsp;(Zip Code) |

---

**(855) 896-8401**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| **Common stock, par value $0.00001 per share** | **AKYA** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On March 6, 2023, Akoya Biosciences, Inc. (the "***Company***") issued a press release announcing its financial condition and results of operations for the period ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

*The information under Item 2.02 of this Current Report on Form 8-K, including the press release furnished as Exhibit 99.1, is being furnished, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing*.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description of Exhibits** |
| 99.1 |  | [Press Release, dated March 6, 2023](akya-20230306xex99d1.htm) |
| &nbsp;&nbsp;104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 6, 2023 | **Akoya Biosciences, Inc.** | **Akoya Biosciences, Inc.** |
|  | By: | */s/ Brian McKelligon* |
|  |  | Brian McKelligon |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance**

March 6, 2023

*Q4 2022 revenue $21.2 million and FY 2022 revenue $74.9 million*

*FY 2023 revenue guidance range $95-98 million*

MARLBOROUGH, Mass.— Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2022.

"Akoya's strong performance in 2022 is a reflection of the robust demand for our leading spatial biology solutions, our thoughtful consideration of market requirements, and sound execution of our financial and strategic plan," said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. "The accelerating adoption of our solutions enabled record setting revenues quarter over quarter throughout the year. We grew our installed base to 934 instruments by year end 2022 and expanded our reagent and analysis tool offerings, to deliver the fastest, simplest, and most flexible spatial biology platform in the market. Furthermore, we made significant progress towards the clinic, where we have a first-mover advantage, by securing biopharma CDx and IVD workflow partnerships, strengthening Akoya's position within the largest spatial biology market segment."

**Fourth Quarter 2022 Financial Highlights**

● Total revenue was $21.2 million in the fourth quarter of 2022, compared to $16.2 million in the prior year period; an increase of 31%.

● Product revenue was $15.7 million in the fourth quarter of 2022, compared to $12.9 million in the prior year period; an increase of 22%.

● Services and other revenue totaled $5.5 million in the fourth quarter of 2022, compared to $3.2 million in the prior year period; an increase of 70%.

● Gross profit was $12.0 million and gross profit margin was 57% in the fourth quarter of 2022.

● 71 instruments were sold in the fourth quarter of 2022; 25 PhenoCyclers, 46 PhenoImagers (which includes Fusion and HT); compared to 46 instruments sold in the prior year period (21 PhenoCyclers, 25 PhenoImagers); an increase of 54%.

● Instrument installed base of 934 as of December 31, 2022; 254 PhenoCyclers, 680 PhenoImagers.

● Combined-unit PhenoCycler-Fusion installed base of 105 as of December 31, 2022.

● $81.2 million of cash, cash equivalents, and marketable securities as of December 31, 2022.

**Full Year 2022 Financial Highlights**

● Total revenue was $74.9 million for the FY 2022 compared to $54.9 million in the prior year; an increase of 36%.

● Product revenue was $57.7 million for the FY 2022, compared to $44.5 million in the prior year; an increase of 30%.

● Services and other revenue totaled $17.2 million for the FY 2022, compared to $10.4 million in the prior year; an increase of 65%.

● Gross profit was $43.4 million and gross profit margin was 58% for the FY 2022.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● 237 instruments were sold throughout the FY 2022; 72 PhenoCyclers, 165 PhenoImagers (which includes Fusion, HT, and Mantra), compared to 147 instruments sold in the prior year; an increase of 61%.

**Fourth Quarter 2022 Business Highlights**

● As of December 31, 2022, there have been 772 total publications featuring Akoya's platform; 57% growth from 493 total publications as of December 31, 2021.

● At the 2022 Society of Immunotherapy of Cancer (SITC) conference November 8-12, 2022, Akoya unveiled the PhenoCode Signature Panels on the PhenoImager instruments and will begin commercial launch of the first five signature IO panels during the first quarter of 2023.

● As highlighted during the 2 <sup>nd</sup> Annual Spatial Day , held virtually on December 15, 2022, Akoya will be launching a suite of solutions throughout 2023 including: PhenoCode Signature Panels for low to mid-plex translational and clinical research studies, PhenoCode Discovery Panels for high-plex protein and RNA discovery studies, ACD's RNAscope for RNA biomarker validation, a multi-slide carrier upgrade on the PhenoCycler-Fusion to double throughput, and cutting-edge partnered software analysis tools.

● At the 2023 Advances in Genome Biology and Technology (AGBT) conference February 6-9, 2023, Akoya presented results from a novel same-section study which showcased the benefits of high-speed imaging via the PhenoCycler-Fusion to simultaneously detect protein and RNA markers across 23 different tissue samples, demonstrating a first-of-its-kind robust and scalable multiomics dataset.

● Announced a strategic partnership with Agilent to accelerate multi-plex tissue analysis adoption in the clinic with a combined end-to-end commercial workflow of reagents, staining, imaging, analysis and services for the benefit of biopharma and CROs to meet spatial diagnostic needs.

**2023 Financial Outlook** 

The Company, based on its current plans and initiatives, expects a full year 2023 revenue guidance range of $95-98 million.

**Webcast and Conference Call Details**

Akoya will host a conference call today, March 6, 2023, at 5:00 p.m. Eastern Time to discuss its fourth quarter and full year 2022 financial results. Investors interested in listening to the conference call are required to <u>register online</u>. A live webcast of the conference call will be available on the "Investors" section of the Company's website at <u>https://investors.akoyabio.com/</u>. The webcast will be archived on the website following the completion of the call for three months.

**Forward-Looking Statements**

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including expectations regarding our ability to market and sell our PhenoCycler and PhenoImager platforms and increase awareness of spatial biology technology, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.

------

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

**About Akoya Biosciences**

As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.

**Investor Contact:**

Priyam Shah

Sr. Director, Investor Relations

Akoya Biosciences

investors@akoyabio.com

**Media Contact:**

Christine Quern

617-650-8497

media@akoyabio.com

------

**AKOYA BIOSCIENCES, INC. AND SUBSIDIARY**

**Condensed Consolidated Balance Sheets *(unaudited)***

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | **December 31, 2022** | **December 31, 2021** |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**74229** | $**113079** |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | **6989** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | **9729** | **9444** |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | **14486** | **9014** |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **6764** | **9277** |
| Total current assets | **112197** | **140814** |
| Property and equipment, net | **10174** | **7487** |
| Demo inventory, net | **2084** | **2548** |
| Intangible assets, net | **20048** | **21150** |
| Goodwill | **18262** | **18262** |
| Operating lease right of use assets, net | **10785** | **—** |
| Financing lease right of use assets, net | **1490** | **—** |
| Other non-current assets | **991** | **646** |
| Total assets | $**176031** | $**190907** |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other current liabilities | $**27147** | $**23198** |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | **3009** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of financing lease liabilities | **620** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | **6279** | **4484** |
| Total current liabilities | **37055** | **27682** |
| Deferred revenue, net of current portion | **2114** | **1330** |
| Long-term debt, net | **63277** | **32471** |
| Contingent consideration liability, net of current portion | **6039** | **7850** |
| Operating lease liabilities, net of current portion | **8203** | **—** |
| Financing lease liabilities, net of current portion | **675** | **—** |
| Other long-term liabilities | **87** | **223** |
| Total liabilities | **117450** | **69556** |
| Total stockholders' equity | **58581** | **121351** |
| Total liabilities and stockholders' equity | $**176031** | $**190907** |

---

------

**AKOYA BIOSCIENCES, INC. AND SUBSIDIARY**

**Consolidated Statements of Operations *(unaudited)***

**(in thousands, except share and per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Year ended**  | **Year ended**  |
|  | **December 31,** <br>**2022** | **December 31,** <br>**2021** | **December 31,** <br>**2022** | **December 31,** <br>**2021** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;Product revenue | $**15708** | $**12921** | $**57650** | $**44477** |
| &nbsp;&nbsp;Service and other revenue | **5511** | **3237** | **17209** | **10440** |
| Total revenue | **21219** | **16158** | **74859** | **54917** |
| Cost of goods sold: |  |  |  |  |
| &nbsp;&nbsp;Cost of product revenue | **6214** | **4090** | **20947** | **14471** |
| &nbsp;&nbsp;Cost of service and other revenue | **2959** | **1842** | **10522** | **6228** |
| Total cost of goods sold | **9173** | **5932** | **31469** | **20699** |
| Gross profit | **12046** | **10226** | **43390** | **34218** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;Selling, general and administrative | **20948** | **19046** | **79653** | **51016** |
| &nbsp;&nbsp;Research and development | **6433** | **5563** | **23211** | **15701** |
| &nbsp;&nbsp;Change in fair value of contingent consideration | **497** | **1023** | **(102)** | **2073** |
| &nbsp;&nbsp;Depreciation and amortization | **1759** | **1374** | **6734** | **4726** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | **29637** | **27006** | **109496** | **73516** |
| Loss from operations | **(17591)** | **(16780)** | **(66106)** | **(39298)** |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;Interest expense | **(1847)** | **(844)** | **(4554)** | **(3115)** |
| &nbsp;&nbsp;Change in fair value of warrant liability | **—** | **—** | **—** | **(2728)** |
| &nbsp;&nbsp;Gain on extinguishment of debt | **—** | **—** | **—** | **2476** |
| &nbsp;&nbsp;Interest income | **564** | **26** | **777** | **91** |
| &nbsp;&nbsp;Other expense, net | **(27)** | **(192)** | **(635)** | **(501)** |
| Loss before benefit (provision) for income taxes | **(18901)** | **(17790)** | **(70518)** | **(43075)** |
| Benefit (provision) for income taxes | **26** | **117** | **(123)** | **140** |
| Net loss | $**(18875)** | $**(17673)** | $**(70641)** | $**(42935)** |
| Dividends accrued on redeemable convertible preferred stock | **—** | **—** | **—** | **(1435)** |
| Adjusted net loss attributable to common stockholders | **(18875)** | **(17673)** | **(70641)** | **(44370)** |
| Net loss per share attributable to common stockholders, basic and diluted | $**(0.50)** | $**(0.47)** | $**(1.87)** | $**(1.65)** |
| Weighted-average shares outstanding, basic and diluted | **38002409** | **37252039** | **37746915** | **26896976** |

---

------